• Comparison, between the two groups, of the percentage of patients for whom the first blood concentration of Tacrolimus evaluated 3 days (D10) after the first administration of Tacrolimus ranges between 10 and 15 ng/ml. [ Time Frame: 10 days ]
  

• Severity of the delayed restart of the renal function evaluated by the number [ Time Frame: 3 months ]
  
• of dialysis; [ Time Frame: 3 months ]
  
• C0 of Tacrolimus at D14, M1, M2 and M3; [ Time Frame: 3 months ]
  
• AUC (0-12h) of Tacrolimus at D14, M1 and M3; [ Time Frame: 3 months ]
  
• Time (in D) to obtain C0 targets of Tacrolimus between 10 and 15 ng/ml [ Time Frame: 3 months ]
  
• Number of dosage schedule adjustments for Tacrolimus necessary to obtaining [ Time Frame: 3 months ]
  
• first C0 target between 10 and 15 ng/ml; [ Time Frame: 1 month ]
  
• Global frequency of the clinical acute rejections; [ Time Frame: 3 months ]
  
• Time and incidence of the first episode of acute rejection proven and not by biopsy [ Time Frame: 3 months ]
  
• Renal graft function at M1 and M3 evaluated by the calculated [ Time Frame: 3 months ]
  
• creatinin clearance; [ Time Frame: 3 months ]
  
• Survival of the patients at M3; [ Time Frame: 3 months ]
  
• Survival of the grafts at M3; [ Time Frame: 3 months ]
  
• Number of adverse events at M3; [ Time Frame: 3 months ]
  
• Pharmacoeconomic impact at M3 evaluated by the duration of the initial [ Time Frame: 3 months ]
  
• hospitalization, the need of care (dialysis, rejection acute, opportunist infection) the frequency and duration of the hospitalizations during the first 3 months [ Time Frame: 3 months ]
  

Drug: Tacrolimus
Administration Twice a day after adjustment to blood level

Inclusion Criteria:

• Patients, male or female, 18 to 65 years old.
• Patients receiving a first or a second isolated renal graft coming from a donor alive or deceased,
• The patients in age to procreate must have a negative test of pregnancy before being included in this study and will have to agree to use effective contraceptive measurements throughout the study.

-Patients able to include/understand the aims and the risks of the study, -having been fully informed and having given their writing consent to take part in this study. Patients unable to write and/or read but having fully understood the oral information given by the investigator and having given their oral consent in the presence of an independent witness. -

Exclusion Criteria:

• Patients who receive several grafts.
• Patients requiring a treatment by azathioprin.
• Pregnant woman or nursing mother
• Patients receiving an incompatible graft ABO.
• Patients receiving or requiring immunosuppressant drugs prohibited by the protocol.
• Patients with a peak of historical antibody equal to or greater than 50% of the panel.
• Patients suffering from serious gastro-intestinal disorders which interfere with their capacity to receive or to absorb an oral form and patients presenting severe diarrhoea.
• Patients with symptomatic GI ulcer HIV or HTLV1 positive patients or their donors
• Patients presenting or having presented in the 5 last years one or several malignant tumours, except baso or spinocellular cutaneous epithelioma successfully treated.
• Patients with systemic infections requiring a treatment at the entry in the study.
• Patients having a leukocyte numeration lower than 2,5.109/l or haemoglobin lower than 5g/dl.
• Patients with drug-addiction whatever it is, or psychiatric disorder which, according to the point of view of the investigator, could invalidate the communication with investigator or interfere with the compliance of the patient.
• Patients who take part simultaneously in another therapeutic test or who received a study treatment less than 30 days before the entry in this study.
• Patients having already been included in this study.
• Patients allergic or intolerant with corticoids, macrolides, Tacrolimus, mycophenolate mofetil or basiliximab